Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sinovac increases stake in Beijing unit
Sinovac paid cash for the 20.56% of Sinovac (Beijing), to China Bioway Biotech Group Co Ltd, Shenzhen Bio-Port Co Ltd and Beijing Keding Co Ltd. Sinovac’s holdings now
Sinovac paid cash for the 20.56% of Sinovac (Beijing), to China Bioway Biotech Group Co Ltd, Shenzhen Bio-Port Co Ltd and Beijing Keding Co Ltd. Sinovac’s holdings now
Under the terms of the new agreement, Albany Molecular Research will provide fee-for-service chemistry research on projects in strategic therapeutic areas identified by Eli Lilly. Specific financial details
In partnership with Cyclone Commerce, GlobalNet will work to centralize the receipt of submissions from regulated industry and other government agencies into a single system. According to InformationWeek,
A Los Angeles Times article reported that Merck executives knew of the health threat posed to children, as a company memo from 1991 stated that six-month-old children receiving
Preliminary data from the phase II trial of Ceplene, conducted in cooperation with Schering-Plough, in combination with PEG-Intron and Rebetol for the treatment of hepatitis C patients who
The new study is designed to evaluate Onconase (ranpirnase) in patients that have shown resistance to other treatments and will assess a new schedule of administration. The results
Zhangjiang Pharmacy is a pharmaceutical distribution company specializing in South East Asia markets including Thailand, Vietnam, and Burma. Many of its customers, especially those from Vietnam and Thailand,
Quinamed (amonafide dihydrochloride) is a novel naphthalimide analog currently in a phase II clinical trial for hormone refractory prostate cancer. In June 2004, ChemGenex investigators reported results from
The license provides Sanwa with exclusive development, manufacturing and marketing rights for the compound, BT16, in Japan and other Asian countries. According to the agreement, Quark will receive
Patients who have received placebo are now being given the option of switching to SU11248, which is a novel, oral multi-targeted cancer therapy combining anti-angiogenic and anti-tumor activity